Velcade/Doxil Approved for Relapsed or Refractory Multiple Myeloma Pts

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 6
Volume 16
Issue 6

The US Food and Drug Administration (FDA) has approved the use of Doxil (doxorubicin liposome injection, Ortho Biotech) in combination with Velcade for Injection (bortezomib, Millennium) to treat patients with multiple myeloma who have not previously received Velcade and have received at least one prior therapy.

ROCKVILLE, Maryland—The US Food and Drug Administration (FDA) has approved the use of Doxil (doxorubicin liposome injection, Ortho Biotech) in combination with Velcade for Injection (bortezomib, Millennium) to treat patients with multiple myeloma who have not previously received Velcade and have received at least one prior therapy.

The approval is based on a preplanned interim analysis from the international phase III randomized, open-label DOXIL-MMY-3001 trial, which compared Doxil/Velcade to Velcade alone in 646 patients with relapsed/refractory multiple myeloma who had not previously received Velcade. The combination significantly improved median time to progression from 6.5 months to 9.3 months (HR 0.55, P < .0001) (see February ONI, page 3).

"This approval means that the Velcade plus Doxil combination offers an important new option for treating relapsed or refractory multiple myeloma," said principal investigator Robert Orlowski, MD, PhD, of the University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill. "This is particularly significant because we need treatment options that improve the prognosis for patients whose disease has not responded to their first round of therapy."

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
Related Content